Renal involvement in ANCA-associated systemic vasculitis

Journal of Nephrology

Volumn 12, Issue 2, 1999, Pages 105-128

  Van Der Woude, Fokko J ^a   Ferrario, Franco ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN A; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; CASE REPORT; CONFERENCE PAPER; ERYTHROCYTE; FEMALE; GLOMERULONEPHRITIS; HUMAN; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; MACROPHAGE; MONOCYTE; NECROTIZING ARTERITIS; ORAL DRUG ADMINISTRATION; PROGNOSIS; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY; KIDNEY DISEASES; MIDDLE AGED; PROGNOSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0032973613     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (155)

1. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-92.
2. Savage COS, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis presentation, pathology and prognosis. QJ Med 1985; 56: 467-83.
3. Croker BP, Lee T, Gunnels JC. Clinical and pathological features of polyarteritis nodosa and its renal-limited variant: primary crescentic and necrotizing glomerulonephritis. Hum Pathol 1987; 18: 38-44.
4. Cameron JS. Renal disease and vasculitis. Pediatr Nephrol 1988; 2: 490-7.
5. Bindi P, Mougenot B, Mentre F, et al. Necrotizing crescentic glomerulonephritis without significant immune deposits: a clinical and serological study. QJ Med 1993; 86: 55-68.
6. Jennette JC, Falk RJ. The pathology of vasculitis involving the kidney. Am J Kidney Dis 1994; 24: 130-41.
7. Jennette JC. Antineutrophil cytoplasmic autoantibody-associated diseases: a pathologist's perspective. Am J Kidney Dis 1991; 18: 164-70.
8. Adu D, Howie AJ, Scott DGI, Bacon PA, McGonigle RJS, Michael J. Polyarteritis and the kidney. QJ Med 1987; 239: 221-37.
9. Boucher A, Droz D, Adafer E, Noel LH. Relationship between the integrity of Bowman's capsule and the composition of cellular crescents in human crescentic glomerulonephritis. Lab Invest 1987; 56: 526-33.
10. Ferrario F, Tadros MT, Napodano P, Sinico RA, Fellin G, D'Amico G. Critical re-evaluation of 41 cases of "idiopathic" crescentic glomerulonephritis. Clin Nephrol 1994; 41: 1-9.
11. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
12. Wilkowsky MJ, Velosa JA, Holley KE, et al. Risk factors in idiopathic renal vasculitis and glomerulonephritis. Kidney Int 1989; 36: 1133-41.
13. Heptinstall RH. Crescentic glomerulonephritis. In Heptinstall RH Ed. Pathology of the kidney (4th edn). Boston: Little Brown 1992; 627-75.
14. Bajema IM, Hagen EC, Ferrario F, et al. Renal granulomas in systemic vasculitis. Clin Nephrol 1997; 48: 16-21.
15. Holdsworth SR, Allen D, Thomson NM, Glasgow EF, Atkins RC. Histochemistry of glomerular cells in animal models of crescentic glomerulonephritis. Pathology 1980; 12: 339-46.
16. Clarke BE, Ham KN, Tange JD, Ryan GB. Origin of glomerular crescents in rabbit nephrotoxic nephritis. J Pathol 1983; 139: 247-58.
17. Ferrario F, Castiglione A, Colasanti G, Barbiano di Belgioioso G, Bertoli S, D'Amico G. The detection of monocytes in human glomerulonephritis. Kidney Int 1985; 28: 513-9.
18. Hancock WW, Atkins RC. Cellular composition of crescents in human rapidly progressive glomerulonephritis identified using monoclonal antibodies. Am J Nephrol 1984; 3: 177-81.
19. Rastaldi MP, Ferrario F, Tunesi S, Yang L, D'Amico G. Intraglomerular and interstitial leukocyte infiltration, adhesion molecules, and interleukin-la expression in 15 cases of antineutrophil cytoplasmic autoantibody associated renal vasculitis. Am J Kidney Dis 1996; 27: 48-57.
20. Brady HR, Denton MD, Jimenez W, Takata S, Palliser D, Brenner BM. Chemoattractants provoke monocyte adhesion to human mesangial cells and mesangial cell injury. Kidney Int 1992; 42: 480-7.
21. Rovin BH, Rumancik M, Tan L, Dickerson J. Glomeruklar expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994; 71: 536-42.
22. Cattell V. Macrophages in acute glomerular inflammation. Kidney Int 1994; 45: 945-52.
23. Matsumoto K, Dowling J, Atkins RC. Production of interleukin 1 in glomerular cell cultures from patients with rapidly progressive crescentic glomerulonephritis. Am J Nephrol 1988; 8: 463-70.
24. Tipping PG, Leong TW, Holdsworth SR. Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbit. Lab Invest 1991; 65: 272-9.
25. Stilmant MM, Bolton WK, Sturgill BC, Schmitt GW and Couser WG. Crescentic glomerulonephritis without immune deposits: clinicopathologic features. Kidney Int 1979; 15: 184-95.
26. Pettersson E, Sundelin B, Heigl Z. Incidence and outcome of pauci-immune necrotizing and crescentic glomerulonephritis in adults. Clin Nephrol 1995; 43: 141-9.
27. D'Agati V, Chander P, Nash M, Mancilla-Jimanez R. Idiopathic microscopic polyarteritis nodosa: ultrastructural observations on the renal vascular and glomerular lesions. Am J Kidney Dis 1986; 7: 95-110.
28. Kussmaul A, Maier R. Über eine bisher nicht beschriebene eigentümliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellahmung einhergeht. Dtsch Arch Klein Med 1866; 1: 484-518
29. Wegener F. Über eine eigenartige rhinogene Granulomatose mit besonderer Beteiligung des Arteriensystems und der Nieren. Beitr Path Anat 1939; 102, 36-8
30. Godman GC, Churg J. Wegener's granulomatosis. Pathology and review of the literature. Arch Pathol 1954; 58: 533-53
31. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. Q J Med 1948;17: 175-202
32. Zeek PM. Polyarteritis nodosa and other forms of necrotizing glomerulonephritis. N Engl J Med 1953; 248: 764-72.
33. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
34. Hagen EC, Andrassy K, Bajema IM et al. The diagnostic value of standardised assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int.1998; 53: 743-58.
35. Shillitoe EJ, Lehner T, Lessof MH, Harrison DFN. Immunological features of Wegener's granulomatosis. Lancet 1974,i: 281-4.
36. Woude FJ van der, Arisz L., Meijer S et al. Wegener's Granulomatosis. A clinicopathological study in twelve patients. Neth J Med 1978; 21:205-20.
37. Short AK, Esnault VL, Lockwood CM. Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. Am J Kidney Dis 1995; 26: 439-45.
38. Allmaras E, Nowack R, Andrassy K et al. rapidly progressive IgA nephropathy with anti-myeloperoxidase antibodies benefits from immunosuppression. Clin Nephrol 1997; 48: 269-73.
39. Faber V, Elling P, Norup G, Mansa B, Nissen NI. An anti-nuclear factor specific for leukocytes. Lancet 1964; ii: 344-5.
40. Wiik A, Munthe E. Complement fixing granulocyte-specific antinuclear factors in neutropenic cases of rheumatoid arthritis. Immunology 1974; 26: 1127-34.
41. Davies DJ, Moran JE, Niall JF. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology. Br Med J 1982; 285: 606
42. Van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
43. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotising and crescentic glomerulonephritis. N EnglJ Med 1988; 318: 1651-7.
44. Hagen EC, Andrassy K, Chernok E et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection .A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR group for ANCA standardization. J Immunol Methods 1993; 159: 1-16.
45. Hagen EC, Andrassy K, Csernok E et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection .A report on the second phase of an international co-operative study on the standardization of ANCA assays. EEC/BCR group for ANCA standardization. J Immunol Methods 1996; 196: 1-15.
46. Cohen Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses in Wegener's Granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11.
47. Markey BA, Warren JS. Use of anti-neutrophil cytoplasmic antibody assay to distinguish between vasculitic disease activity and complications of cytotoxic therapy. Am J Clin Pathol 1994; 102: 589-94.
48. Maguchi S, Takizawa M, Miyatake Y et al. Antineutrophil cytoplasmic antibody (C-ANCA) levels in relation to the treatment of Wegener's granulomatosis. Nippon Jibiinkoka Gakkai Kaiho 1995; 98: 974-83.
49. De'Oliviera J, Gaskin G, Dash A et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380-9.
50. Cohen P, Guillevin L, Baril L et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow up of 53 patients. Clin Exp Rheumatol 1995; 13: 193-8.
51. Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995; 15: 201-7.
52. Kerr GS, Fleisher TA, Hallahan CW et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-71.
53. Lane SE, Scott DGI, Watts RA, Heaton A. Epidemiology of renal vasculitis 1995-97(Abstr). Clin Exp Immunol 1998; 112 (Suppl 1): 32.
54. Watts RA, Carruthers DM, Scott DGI. Epidemiology of systemic vasculitis: changing incidence or definition? Semin Arthritis Rheum 1995; 25: 28-34.
55. Cotch MF, Hoffman GS, Yerg DE et al.The epidemiology of Wegener's granulomatosis. Arthritis Rheum 1996; 39: 87-92.
56. Rheinhold-Keller E, Zeidler A, Möck C et al. Epidemiology of primary systemic vasculitides in North and South Germany (Abstr) Sarcoidosis, vasculitis and diffuse lung diseases 1996; 13: 272.
57. Scott DGI, Bacon PA, Eliott PJ et al. Systemic vasculitis in a district hospital 1972-80. Clinical and laboratory features, classification and prognosis of 80 cases. Q J Med 1982; 203: 292-311.
58. Carruthers DM, Watts RA, Symmons DPM et al. Wegener's granulomatosis-increased incidence or increased recognition? Br J Rheumatol 1996; 35: 142-5.
59. Andrews M Edmonds M, Campbell A et al. Systemic vasculitis in die 1980s-Is there an increasing incidence of Wegener's granulomatosisand microscopic polyangiitis? J R Coll Phys 1990; 24: 284-8.
60. Raynauld JP, Bloch D, Fries J. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis. J Rheumatol 1993; 20: 1524-6
61. Dale DC, Fauci AS, Wolff SM. The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with WG. Arthritis Rheum 1973; 16: 657-64.
62. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-9.
63. Ewert BH, Jennette JC, Falk RJ. The pathogenic role of anti-neutrophil cytoplasmic autoantibodies. Am J Kidney Dis 1991; 18: 188-95.
64. Brouwer E, Huitema MG, Mulder AHL et al. Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. Kidney Int 1994; 45: 1120-31.
65. Nowack R, Flores Suarez F, Van der Woude FJ. New developments in pathogenesis of vasculitis. Curr Opin Rheumatol 1998; 10: 3-11.
66. Savage CO, Gaskin G, Pusey CD et al. Myeloperoxidase binds to vascular endothelial cells, is recognised by ANCA and can enhance complement dependent cytotoxicity. Adv Exp Med Biol 1993; 336: 121-3.
67. Van de Wiel BA, Dolman KM, van der Meer-Gerritsen CH et al. Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase-3 activity. Clin Exp Immunol 1992; 90: 409-14.
68. Mark EJ, Matsubura O, Tan Liu NS et al. The pulmonary biopsy in the early diagnosis of Wegener's (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum Pathol 1988; 19: 1065-71.
69. Van der Woude FJ, van Es LA, Daha MR. The role of the cAN-CA antigen in the pathogenesis of Wegener's granulomatosis. A hypothesis based on both humoral and cellular mechanisms. Neth J Med 1990; 36: 161-71.
70. Rasmussen N, Petersen J. Cellular immune responses and pathogenesis in cANCA positive vasculitides. J Autoimmun 1993; 6: 227-36.
71. Brouwer E, Stegeman C, Huitema M et al. T-cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis. Clin Exp Immunol 1994; 98: 448-53.
72. Petersen J, Rasmussen N, Szpirt W et al. T lymphocyte proliferation to neutrophil cytoplasmic antigens in Wegener's granulomatosis. Am J Kidney Dis 1991; 18: 205.
73. Harper JM, Thiru S, Lockwood CM et al. Myeloperoxidase autoantibodies distinguish vasculitis mediated by anti-neutrophil cytoplasm antibodies from immune complex disease in MRL/Mp-lpr/lpr mice: a spontaneous model for human microscopic angiitis. Eur J Immunol 1998; 28: 2217-26.
74. Cherry, Engelman RW, Wang BY, Kinjoh K et al. Calorie restriction delays the crescentic glomerulonephritis of SCG/Kj mice. Proc Soc Exp Biol Med 1998; 218: 218-22.
75. Kobayashi K, Shibata T, Sugisaki T. Aggravation of rat Masugi nephritis by heterologous anti-rat myeloperoxidase antibodies. Clin Exp Immunol 1993; 93: s20.
76. Brouwer E, Huitema MG, Klok PA et al. Antimyeloperoxidase-associated proliferative glomerulonephritis-an animal model. J Exp Med 1993; 177: 905-14.
77. Yang JJ, Jennette JC, Falk RJ. Immune complex glomerulonephritis is induced in rats immunized with heterologous myeloperoxidase. Clin Exp Immunol 1994; 97: 466-73.
78. Nowack R, Birck R, Van der Woude FJ. Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. Am J Kidney Dis in press
79. Dolman KM, Gans ROB, Vervaat TJ et al. Vasculitis and anti-neutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651-2.
80. Masor JJ, Gal AA, Livolsi A. Case report: Hashimoto thyroiditis associated with Wegener's granulomatosis. Am J Med Sci 1994; 308: 112-4.
81. Armbruster C, Vetter N. Wegenersche Granulomatose mit Milzbeteiligung und Thyreoiditis Iymphomatosa Hashimoto. Pneumology 1991; 45: 28-31.
82. Sugimoto A, Sugimoto S, Tanaka M et al. Wegener's granulomatosis and insulin dependent diabetes mellitus (IDDM) Jpn J Med 1989; 28: 374-8.
83. Elkon KB, Sutherland DC, Rees RJ et al.HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum 1983; 26: 102-5.
84. Coulthart A, Fisher M, Gaskin G et al. HLA Class II genes in ANCA-associated vasculitis (Abstr.) Clin Exp Immunol 1998; 112 (Suppl 1): 53.
85. Katz P, Alling DW, Haynes BF et al. Association of Wegener's granulomatosis with HLA-B8. Clin Immunol Immunopathol 1979; 14: 268-70.
86. Beigel A, Lehmann H, Westphal E. The spectrum of histocompatibility antigens (HLA) in Wegener's granulomatosis. Arch Otolaryngol 1980; 233: 157-60.
87. Papiha SS, Murty GE, Ad Hia A et al. Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann Rheum Dis 1992; 51: 246-8.
88. Zhang L, Jayne DR, Zhao MH et al. Distribution of MHC class II alleles in primary systemic vasculitis. Kidney Int 1995; 47: 294-8.
89. Spencer SJW, Burns A, Gaskin G et al. HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int 1992; 41: 1059-63.
90. Müller GA, Gebhardt M, Kompf J et al. Association between rapidly progressive glomerulonephritis and the properdin factor BfF and different HLA-D region products. Kidney Int 1984; 25: 115-8.
91. Hagen EC, Stegemann CA, Amaro JD, et al. Decreased frequency of HLA-DR13DR6 in Wegener's Granulomatosis. Kidney Int 1995; 48: 801-5.
92. Esnault VL, Testa A, Audrain M et al. Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43: 1329-32.
93. Mazodier P, Elzouki ANY, Segelmark M, et al. Systemic necrotising vasculitides in severe al-antitrypsin deficiency. QJ Med 1996; 86: 599-611.
94. Edberg JC, Wainstein E, Wu J. et al. Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis. Exp Clin Immunogenet 1997; 14: 183-95.
95. Gregorini G, Ferioli A, Donato F. Association between silica exposure and necrotizing crescentic glomerulonephritis with pANCA and aMPO antibodies: a hospital-based case-control study. Adv Exp Med Biol 1993; 336: 435-40.
96. Nuyts GD, van Vlem E, de Vos A et al. Wegener's granulomatosis is associated to exposure to silicon compounds: a case-control study. Nephrol Dial Transplant 1995; 10: 1162-5.
97. Satterly KK, Hogan SL, Nachman PH et al. ANCA-associated diseases with renal involvement but not lupus nephritis are associated with silica exposure (Abstr). Clin Exp Immunol 1998; 112 (Suppl1): 25.
98. Yaqoob M, Bell GM, Percy DF et al. Primary glomerulonephritis and hydrocarbon exposure: a case-control study and literature review. QJ Med 1992; 83: 409-18.
99. Bell GM, Gordon ACH, Lee P et al. Proliferative glomerulonephritis and exposure to organic solvents. Nephron 1985; 40: 161-5.
100. Pai P, Bone JM, Bell GM. Hydrocarbon exposure and glomerulonephritis due to systemic vasculitis (letter). Nephrol Dial Transplant 1998; 13: 1321-3.
101. Phanuphak P, Kohler PF. Onset of polyarteritis nodosa during allergic hyposensitization treatment. Am J Med 1980; 20: 1429-31.
102. Mader R, Narendan A, Lewtas J et al. Systemic vasculitis following influenza vaccination-report of 3 cases and literature review. J Rheumatol 1993; 20:1429-31.
103. Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 1995; 20: 1010-36.
104. Pinching AJ, Rees AJ, Pussell BA et al.Relapses in Wegener's Granulomatosis: the role in infection. Br Med J 1980; 281: 836-8.
105. Stegemann CA, Cohen Tervaert JSV, Sluiter WJ et al. Association of chronic nasal carriage of staphylococcus aureus and higher relapse rates in Wegener's Granulomatosis. Ann Int Med 1994; 120: 12-7.
106. Walton EW. Giant cell granuloma of the respiratory tract. Br Med J 1985; 2: 265-70.
107. Carrington CB, Liebow AA. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966; 41: 497-527.
108. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Int Med 1967; 67: 393-8.
109. Novack SN, Pearson CM. Cyclophosphamide therapy in Wegener's granulomatosis. N Engl J Med 1971; 284: 938-42.
110. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune reponse in Wegener's granulomatosis. N Engl J Med 1971; 285: 1493-6.
111. Fauci AS, Katz P, Haynes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979; 301: 235-8.
112. Hoffman GS, Leavitt RY, Fleisher TA et al. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-10.
113. Guillevin L, Cordier JF, Lhote F et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
114. Adu D, Pall A, Luqmani RA et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJ Med 1997; 90: 401-9.
115. Koldingsnes W, Gran JT, Omdal R, Husby G. Wegener's granulomatosis: long-term follow-up of patients treated with pulse cyclophosphamide. Br J Rheumatol 1998; 37: 659-64.
116. Haubitz M, Schellong S, Göbel U et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998; 41: 1835-44.
117. Rasmussen N. Consensus therapeutic regimens for ANCA-associated systemic vasculitis. The European Community Systemic Vasculitis Study Group. Lancet 1997; 349:1029-30.
118. Nowack R, Birck R, van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774.
119. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol 1998; 9: 842-52.
120. Reinhold-Keller E, de Groot K, Rudert H et al. Response to trimethoprim/ sulfamethoxazole in WG depends on the phase of the disease. QJ Med 1996; 89:15-23.
121. Stegeman CA, Tervaert JWC, dejong PE et al. Trimethoprimsulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's Granulomatosis. N Engl J Med 1996; 335: 16-20.
122. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322-9.
123. Sneller MC, Hoffman GS, Talar-Williams C et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
124. De Groot K, Rheinhold-Keller E, Tatsis E. et al. Therapy for the maintenance of remission in sixty-five patients with generalised Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052-61.
125. Haubitz M, Koch KM, Brunkhorst R. Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol Dial Transplant 1998; 13: 2074-6.
126. Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35: 1150-3.
127. Blum M, Andrassy K et al. Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 1997; 235: 599-602.
128. Lockwood CM, Thiru S, Stewart S et al. Treatment of refractory Wegener's granulomatosis with humanised monoclonal antibodies. QJ Med 1996; 89: 903-12.
129. Hagen EC, de Keizer RJW, Andrassy K et al. Compassionate treatment of Wegener's granulomatosis with rabbit anti-thymocyte globulin. Clin Nephrol 1995; 43: 351-9.
130. D'Amico G, Sinico R, Fornasieri A, Ferrario F et al. Effect of intensive plasma exchange in rapidly progressive crescentic glomerulonephritis. Int J Artif Organs 1983; 6 Suppl 1: 3-9.
131. Rees AJ, Pusey CD. Plasma exchange in systemic vasculitis. Neth J Med 1990; 36: 103-6.
132. Frasca GM, Zoumparidis NG, Borgnino LC et al. Plasma exchange treatment in rapidly progressive glomerulonephritis associated with anti-neutrophil cytoplasmic autoantibodes. Int J Artif Organs 1992; 15: 181-4.
133. Gianvita A, Trompeter RS, Barratt TM et al. Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child 1996; 75: 186-90.
134. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic antibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-9.
135. Gayraud M, Guillevin L, Cohen P et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French co-operative study group for vasculitides. Br J Rheumatol 1997; 36: 1290-7.
136. Martin-Suarez I, D'Cruz D, Mansoor M et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-7.
137. Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Int Med 1998; 129: 370-4.
138. Matteson EL, Gold KN, Bloch, DA et al. Long-Term surviral of patients with Wegener's Granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am J Med 1996; 101: 129-34.
139. Van der Woude FJ, Hoorntje SJ, Weening JJ et al. Renal involvement in Wegener's Granulomatosis. Report of three unusual cases. Nephron 1982; 32: 185-7.
140. Fransscn CFM, Gans ROB, Arend B et al. Differences between anti-myeloperoxidase and anti-proteinase-3 associated renal disease. Kidney Int 1995; 47: 193-199.
141. Franssen CFM, Stegeman CA, Oost-Kort WW et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998; 9: 1915-23.
142. Cohen RD, Conn DL, Ilstrup DM. Clinical features, prognosis, and response to treatment in polyarthritis. Mayo Clin Proc 1980; 55:146-150.
143. Pinching AJ, Lockwood CM, Pussell BA, Rees AJ, Sweny P, Evans DJ, Bowley N, Peters DK. Wegener's granulomatosis: Observations on 18 patients with severe renal disease. QJ Med 1983; 52: 435-60.
144. Serra A, Cameron JS, Turner DR, Hartley B, et al. Vasculitis affecting the kidney; presentation, histopathology and long-term outcome. QJ Med 1984; 53: 181-207.
145. Wilkowski MJ, Velosa JA, Holley KE et al. Risk factors in idiopathic renal vasculitis and glomerulonephritis. Kidney Int 1989; 36:1133-41.
146. Fogazzi GB, Imbasciati E, Moroni G, Scalia A, Mihatsch MJ, Ponticelli C. Reversible acute renal failure from gross haematuria due to glomerulonephritis: not only in IgA nephropathy and not associated with intratubular obstruction. Nephrol Dial Transplant 1995; 10 (5): 624-629.
147. Ralston DR, Marsh CB, Lowe MP, Wevers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha-1-antitrypsin, and Fc gamma receptors. J Clin Invest 1997; 100: 1416-24
148. Casselman BL, Kilgore KS, Miller BF, Warren JS. Antibodies to neutrophil cytoplasmic antigens induce monocyte chemoattractive protein-1 secretion from human monocytes. J Lab Clin Med 1995; 126: 495-502
149. Erlich JH, Holdsworth SR, Tipping PG. Tissue factor initiates glomerular fibrin deposition and promotes major histocompatibility complex class II expression in crescentic glomerulonephritis. Am J Pathol 1997; 150: 873-80.
150. Haver HA, Bajerna IM, Hermans J, et al. Analysis of 74 renal biopsies of patients with ANCA-associated systemic vasculitis with renal involvement. Submitted for publication.
151. Palmer A, Cairns T, Dische F, et al. Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 1991; 6(8): 536-42.
152. Esnault VL, Testa A, Jayne DR, Soulillou JP, Guenel J. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 1993; 65(2): 180-49.
153. Coremans IE, Hagen EC, van der Voort EA, van der Woude FJ, Daha MR, Breedveld FC. Autoantibodies to neutrophil cytoplasmic enzymes in Felty's syndrome. Clin Exp Rheumatol 1993; 11: 255-62.
154. Schnitzler N, Haase G, Podbielski A, Lutticken R., Schweizer KG. A co-stimulatory signal through ICAM-beta2 integrin-binding potentiates neutrophil phagocytosis. Nat Med 1999; 5: 231-5.
155. Emmanouilides CE, Lianou PE, Bassaris HP, Papavassiliou JT. Trimethoprim, sulphamethoxazole, bacterial adhesion and polymorphonuclear leucocyte function. J Antimicrob Chemother 1990; 26: 803-12.